KERYX BIOPHARMACEUTICALS INC's ticker is KERX and the CUSIP is 492515101. A total of 142 filers reported holding KERYX BIOPHARMACEUTICALS INC in Q3 2015. The put-call ratio across all filers is 1.06 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $302,000 | -12.5% | 88,800 | -3.3% | 0.03% | -15.2% |
| Q2 2018 | $345,000 | +15.8% | 91,800 | +26.1% | 0.03% | +13.8% |
| Q1 2018 | $298,000 | -5.4% | 72,800 | +7.4% | 0.03% | -6.5% |
| Q4 2017 | $315,000 | -37.0% | 67,800 | -3.7% | 0.03% | -38.0% |
| Q3 2017 | $500,000 | -1.8% | 70,400 | 0.0% | 0.05% | -7.4% |
| Q2 2017 | $509,000 | +12.9% | 70,400 | -3.8% | 0.05% | +10.2% |
| Q1 2017 | $451,000 | +5.9% | 73,200 | +0.7% | 0.05% | +2.1% |
| Q4 2016 | $426,000 | +11.2% | 72,700 | +0.7% | 0.05% | +11.6% |
| Q3 2016 | $383,000 | -25.8% | 72,200 | -7.4% | 0.04% | -24.6% |
| Q2 2016 | $516,000 | +100.8% | 78,000 | +41.6% | 0.06% | +96.6% |
| Q1 2016 | $257,000 | -12.9% | 55,100 | -6.0% | 0.03% | -14.7% |
| Q4 2015 | $295,000 | +36.6% | 58,600 | -4.6% | 0.03% | +30.8% |
| Q3 2015 | $216,000 | -37.6% | 61,400 | +76.9% | 0.03% | -29.7% |
| Q2 2015 | $346,000 | – | 34,700 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 700,273 | $10,770,000 | 5.76% |
| HARVEY CAPITAL MANAGEMENT INC | 932,400 | $14,340,000 | 5.13% |
| Camber Capital Management LP | 3,000,000 | $46,140,000 | 3.02% |
| Baupost Group | 10,539,986 | $162,105,000 | 2.64% |
| SECTORAL ASSET MANAGEMENT INC | 3,741,656 | $57,547,000 | 2.44% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,884,409 | $59,742,000 | 2.40% |
| Knoll Capital Management, LLC | 200,000 | $3,076,000 | 1.37% |
| DAFNA Capital Management LLC | 92,400 | $1,421,000 | 1.35% |
| NORTHPOINTE CAPITAL LLC | 892,011 | $13,719,000 | 1.32% |
| Rhenman & Partners Asset Management AB | 240,000 | $3,691,000 | 1.10% |